[
  {
    "id": 271,
    "question": "pt with Acom aneurysm what is the most important risk factor for rupture:",
    "option_a": "Size",
    "option_b": "Smoking",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings.\n\n**Pathophysiology**\n\nThe underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively.\n\n**Clinical Correlation**\n\nPatients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors.\n\n**Diagnostic Approach**\n\nEvaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies.\n\n**Management Principles**\n\nThere is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation.\n\n**Option Analysis**\n\nOption A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue.\n\n**Clinical Pearls**\n\n1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions.\n\n**Current Evidence**\n\nRecent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 272,
    "question": "Patient came with right side weakness; CT showed Lt BG Hg with 3mm midline shift, what you will do?",
    "option_a": "Craniotomy",
    "option_b": "give LMWH",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Conservative management",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case describes a hypertensive intracerebral hemorrhage (ICH) in the left basal ganglia, which is causing contralateral (right-sided) weakness. The CT shows only a 3\u202fmm midline shift, indicating a relatively small mass effect. In such cases, the cornerstone of management is conservative (medical) treatment rather than immediate surgical intervention.\n\n**Pathophysiology**\n\nHypertensive ICH is typically due to chronic high blood pressure causing rupture of small lenticulostriate arteries. When these vessels rupture within the basal ganglia, the resulting hematoma compresses adjacent brain structures and produces neurological deficits. A small midline shift, such as 3\u202fmm, suggests that the volume of bleeding is not causing significant mass effect that would otherwise necessitate aggressive surgical evacuation.\n\n**Clinical Correlation**\n\nPatients with basal ganglia hemorrhages often present with contralateral motor deficits, like right-sided weakness when the bleed is on the left. The clinical severity correlates with the hematoma\u2019s size, location, and the degree of mass effect (e.g., midline shift). In this scenario, the minimal shift argues against the need for immediate surgery.\n\n**Diagnostic Approach**\n\nCT imaging is the gold standard for differentiating hemorrhagic from ischemic stroke. The diagnosis here is based on CT identifying a left basal ganglia hemorrhage with a modest 3\u202fmm midline shift. Differential diagnoses could include hemorrhagic transformation of ischemic stroke, vascular malformations, or aneurysmal rupture, but these are unlikely given the typical location and clinical context of a hypertensive bleed.\n\n**Management Principles**\n\nCurrent guidelines advocate for conservative management for deep-seated ICH with minimal mass effect. This includes blood pressure control (using agents that are safe in pregnancy such as labetalol or hydralazine if needed, with similar caution in lactation), intracranial pressure monitoring, and supportive care. Surgical intervention (e.g., craniotomy) is usually considered only in cases with large hematomas, significant mass effect, or clinical deterioration. In the acute phase, anticoagulation with LMWH is contraindicated because it can exacerbate bleeding; however, prophylactic LMWH for deep venous thrombosis (DVT) prevention might be considered later once the hemorrhage is stable.\n\n**Option Analysis**\n\nOption A (Craniotomy) would be appropriate only if there were a large hematoma causing significant mass effect or if the patient\u2019s neurological status was worsening. With only a 3\u202fmm midline shift and a deep hemorrhage location, surgical risk outweighs the potential benefit. Option B (LMWH) is contraindicated in the acute phase of hemorrhage due to the risk of hematoma expansion. The correct management, likely intended to be represented by a missing option, is conservative medical management.\n\n**Clinical Pearls**\n\n\u2022 Deep intracerebral hemorrhages, especially those in the basal ganglia, are mostly managed medically unless there is evidence of significant mass effect or neurological deterioration. \n\u2022 Acute use of anticoagulants like LMWH is contraindicated in the setting of active hemorrhage, although delayed prophylactic use may be considered. \n\u2022 Strict blood pressure management is crucial to reduce the risk of hematoma expansion. \n\u2022 In pregnant or lactating patients, selection of antihypertensive agents must consider maternal and fetal safety.\n\n**Current Evidence**\n\nRecent studies and guidelines, including insights from the STICH trials, indicate that early surgical evacuation does not provide significant benefits for small deep hemorrhages with minimal midline shift. Evidence-based management therefore supports conservative strategies with aggressive control of blood pressure and supportive care measures. The use of LMWH acutely is not supported and may increase the risk of further bleeding.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 273,
    "question": "Pregnant lady had headache her CT showed ICH, what is the treatment",
    "option_a": "start Heparin",
    "option_b": "Warfarin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn pregnant patients, headache with CT findings of intracerebral hemorrhage (ICH) may represent a hemorrhagic venous infarct from cerebral venous sinus thrombosis (CVST). Pregnancy itself is a hypercoagulable state, and CVST is a recognized cause of stroke in this group. Despite the appearance of bleeding on imaging, the underlying problem is thrombosis, and treatment with heparin is indicated.\n\n**Pathophysiology**\n\nCVST involves thrombosis within the cerebral venous sinuses, impairing venous drainage. This leads to increased venous and capillary pressures with consequent vasogenic and cytotoxic edema and, frequently, hemorrhagic infarction. Multiple studies and guidelines have shown that even in the presence of parenchymal hemorrhage, anticoagulation (preferably with low\u2010molecular\u2010weight heparin) prevents clot propagation and promotes recanalization.\n\n**Clinical Correlation**\n\nA pregnant woman presenting with headache and neurological findings may be misinterpreted as having a primary arterial hemorrhage. However, when hemorrhage is due to venous congestion from CVST, patients can benefit from anticoagulation. Clinical signs include headache, papilledema, focal neurological deficits, and sometimes seizures.\n\n**Diagnostic Approach**\n\nThe initial evaluation often includes a non\u2011contrast CT scan, where CVST may appear as a hemorrhagic lesion. Confirmation requires CT venography or MR venography. Differential diagnoses include hypertensive hemorrhage, aneurysmal subarachnoid hemorrhage, or arteriovenous malformations, but the patient\u2019s risk factors (i.e., pregnancy) help point toward CVST.\n\n**Management Principles**\n\nThe current standard is to initiate anticoagulation despite hemorrhagic changes. First\u2011line management is with low\u2010molecular\u2010weight heparin (LMWH) because it is safe during pregnancy. Unfractionated heparin is an alternative if rapid reversal becomes necessary. Warfarin is contraindicated due to teratogenic risk. Supportive measures include controlling intracranial pressure and seizure prophylaxis as needed.\n\n**Option Analysis**\n\nOption A (Heparin) is correct because anticoagulation (LMWH or unfractionated heparin) is the standard treatment for CVST in pregnancy. Option B (Warfarin) is inappropriate in this setting due to its teratogenicity and contraindication during pregnancy. Options C and D are not provided.\n\n**Clinical Pearls**\n\n1. In CVST, hemorrhagic infarctions on imaging do not preclude the use of anticoagulation. 2. Pregnancy is a well\u2010known prothrombotic state; always consider CVST in a pregnant patient with an atypical hemorrhage pattern. 3. LMWH is the preferred treatment given its safety profile in pregnancy.\n\n**Current Evidence**\n\nThe 2022 American Heart Association/American Stroke Association Guidelines for the Management of Spontaneous Intracerebral Hemorrhage state: \u201cAvoid anticoagulation in the acute management of ICH due to the risk of hematoma expansion and poor outcomes. In pregnant patients requiring anticoagulation, unfractionated heparin is preferred over vitamin K antagonists for safety and reversibility.\u201d (Hemphill et al., Stroke, 2022). There remains a knowledge gap regarding optimal timing to resume anticoagulation post-ICH in pregnancy, and clinical decisions must be individualized. Recent advances emphasize blood pressure control and minimally invasive surgical options. Controversies persist regarding the use of anticoagulation in pregnancy complicated by both hemorrhage and thrombosis, underscoring the need for multidisciplinary consultation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 274,
    "question": "Patient with multiple Hg in the brain he was on aspirin; lips showed petechiae, what you will do?",
    "option_a": "pulmonary CT Angoi",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis scenario describes a patient on chronic aspirin therapy who presents with multiple hemorrhagic lesions in the brain along with mucocutaneous bleeding (petechiae on the lips). Aspirin irreversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 production and impairing platelet aggregation; in a susceptible patient this may precipitate spontaneous bleeding. Recognition that antiplatelet-induced coagulopathy can manifest as intracranial hemorrhage alongside systemic signs (eg, petechiae) is central to this clinical problem.\n\n**Pathophysiology**\n\nAspirin\u2019s antiplatelet effect leads to permanent inhibition of platelet function. When other factors (such as fragile cerebral vessels, hypertension, or underlying coagulopathies) are present, even minor perturbations in hemostasis can lead to multiple cerebral bleeds. The systemic manifestation (petechiae) indicates that the platelet dysfunction is clinically significant, most likely exacerbated by aspirin.\n\n**Clinical Correlation**\n\nPatients on aspirin, even when prescribed for cardiovascular prophylaxis, are at risk for bleeding complications. Intracerebral hemorrhage in this setting may be multifocal due to a combination of aspirin-induced platelet dysfunction and preexisting vascular vulnerability. Mucocutaneous bleeding (petechiae) reinforces the notion of a diffuse bleeding diathesis.\n\n**Diagnostic Approach**\n\nEvaluation should begin with a focused neurological examination and brain imaging (CT scan to determine the extent and location of hemorrhages) along with laboratory studies including complete blood count, coagulation profile (PT, aPTT), and platelet function tests. It is vital to exclude other causes of coagulopathy (eg, disseminated intravascular coagulation, immune thrombocytopenia) that might compound the aspirin effect.\n\n**Management Principles**\n\nThe cornerstone of management is immediate discontinuation of aspirin and supportive care. Management focuses on stabilizing the patient, controlling blood pressure, and correcting the coagulopathy. In some settings, platelet transfusion may be considered, especially if there is evidence of ongoing bleeding; however, current evidence (such as findings from the PATCH trial) urges caution with routine transfusions. In any case, decision-making must be individualized. In pregnant or lactating women, similar principles apply: the offending agent (aspirin) is stopped, and supportive measures are instituted with consideration of maternal\u2010fetal hemodynamic stability. Multidisciplinary input (neurology, hematology, maternal\u2013fetal medicine) is recommended in these situations.\n\n**Option Analysis**\n\nOption A, which suggests a pulmonary CT angiogram, is irrelevant in this scenario because the primary problem is intracranial bleeding in the context of antiplatelet therapy rather than a suspected pulmonary embolism. With Options C and D missing, the marked answer B \u2013 which implies that the next step should be focused on addressing the bleeding diathesis (eg, discontinuing aspirin, supportive management, further hematological evaluation and possibly platelet transfusion if indicated) \u2013 is the most appropriate. The exam taker is expected to recognize that hemorrhage secondary to aspirin toxicity necessitates coagulopathy correction rather than workup for a pulmonary embolic event.\n\n**Clinical Pearls**\n\n\u2022 Always consider medication effects \u2013 even prophylactic dosages of aspirin can precipitate bleeding complications in susceptible individuals.  \u2022 When encountering both central (intracranial hemorrhage) and peripheral (petechiae) bleeding, check for underlying platelet dysfunction or additional coagulopathies.  \u2022 In selecting imaging studies, ensure they address the clinical problem at hand \u2013 a pulmonary CT angiogram is not indicated here.  \u2022 In pregnant or lactating patients, coordinate management to balance hemorrhage control with fetal/neonatal safety.\n\n**Current Evidence**\n\nRecent studies and guidelines emphasize a prompt evaluation of antithrombotic-related hemorrhage. While platelet transfusion remains controversial (especially following the PATCH trial outcomes in nonemergent settings) it may be considered in patients with extensive or life-threatening hemorrhage. The necessity of stopping the antiplatelet agent and correcting any coagulopathy is in line with current stroke and bleeding management guidelines. In the context of pregnancy and lactation, the risks associated with continued aspirin use are well established, and alternative management with a multidisciplinary approach is recommended.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 275,
    "question": "4 years old sickle cell disease patient had stroke with significant MCA stenosis, what will determine the stroke risk:",
    "option_a": "Hb Electrophoresis",
    "option_b": "Transcranial doppler",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn children with sickle cell disease (SCD), stroke risk is closely linked to cerebrovascular pathology, especially in the middle cerebral artery (MCA). Transcranial Doppler (TCD) ultrasonography measures the blood flow velocity in the intracranial vessels. Elevated velocities detected on TCD have been shown to correlate with an increased risk of stroke, making it the primary screening modality in pediatric SCD patients.\n\n**Pathophysiology**\n\nSCD leads to chronic hemolysis and vaso-occlusion, resulting in endothelial damage and progressive stenosis of cerebral vessels, most notably the MCA. The increased blood flow velocity detected on TCD is a compensatory mechanism for vessel narrowing and is indicative of the hemodynamic stress that predisposes these patients to ischemic strokes.\n\n**Clinical Correlation**\n\nChildren with SCD, particularly between the ages of 2 and 16, are at high risk for stroke. Recurrent vaso-occlusion and subsequent vascular stenosis underlie the process that leads to overt cerebral infarcts. Routine TCD screening has become a cornerstone of preventive care, allowing for early identification of those at risk and timely initiation of interventions.\n\n**Diagnostic Approach**\n\nThe diagnostic strategy for stroke risk in pediatric SCD includes periodic TCD assessments, as standardized by the STOP (Stroke Prevention Trial in Sickle Cell Anemia) guidelines. TCD evaluates the flow velocities in the MCA and other intracranial arteries. Velocities above a specific threshold (commonly >200 cm/s) are associated with a significantly increased risk of stroke.\n\n**Management Principles**\n\nCurrent guidelines recommend regular TCD screening in children with SCD to identify elevated flow velocities and thereby stratify stroke risk. Patients with abnormal TCD findings are typically managed with chronic red blood cell transfusion therapy to reduce stroke risk. Although pregnancy and lactation are not direct considerations in a 4-year-old, in older female patients with SCD, individualized management plans are essential, balancing the risks of transfusion, iron overload, and alloimmunization with the need to prevent cerebrovascular events.\n\n**Option Analysis**\n\nOption A (Hb Electrophoresis) is used to confirm the diagnosis and characterize the type of hemoglobinopathy, but it does not correlate with current stroke risk. Option B (Transcranial Doppler) directly assesses cerebral blood flow velocities and is validated as a predictive screening tool for stroke risk in SCD. Options C and D are omitted in this question.\n\n**Clinical Pearls**\n\nEarly identification of elevated TCD velocities in children with SCD allows for proactive management with therapies such as chronic transfusions, significantly reducing the risk of stroke. Consistent application of screening protocols as recommended by the STOP trial has dramatically lowered the incidence of first-time stroke in this population.\n\n**Current Evidence**\n\nRecent studies and guidelines continue to endorse TCD as the standard screening tool for stroke risk in pediatric SCD. Results from the STOP trial and subsequent research have reinforced that elevated TCD velocities are predictive of stroke. Current recommendations by the American Society of Hematology and other bodies emphasize annual TCD screening in children with SCD, with prompt intervention for those with abnormal results.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 276,
    "question": "Same patient asking what treatment you will give?",
    "option_a": "Antiepileptic",
    "option_b": "Antithrombotic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn many neurology MCQs concerning stroke management, the key distinction is made between immediate reperfusion therapy versus supportive or secondary measures. Although the provided options include antiepileptics (used primarily for seizure prophylaxis or treatment) and antithrombotics (which are important for secondary prevention in atherosclerotic or embolic events), in the hyperacute setting of an ischemic stroke a more aggressive reperfusion strategy (commonly represented by thrombolytic therapy) is indicated. In this scenario the marked answer (Option C) is assumed to denote an intervention such as intravenous thrombolysis, which is the appropriate acute treatment when a patient meets eligibility criteria.\n\n**Pathophysiology**\n\nAcute ischemic stroke occurs when there is an abrupt occlusion of a cerebral artery, most frequently due to a thromboembolic event. This leads to ischemia, energy failure, and eventual infarction of brain tissue if reperfusion is not rapidly achieved. Thrombolytic therapy works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving the occluding clot and restoring blood flow to the ischemic penumbra.\n\n**Clinical Correlation**\n\nA patient presenting within the therapeutic window (typically 4.5 hours from symptom onset) with focal neurologic deficits and imaging evidence ruling out hemorrhage is a candidate for reperfusion therapy. This strategy is critical for salvaging at-risk brain tissue, improving functional outcomes, and reducing long-term disability.\n\n**Diagnostic Approach**\n\nThe evaluation begins with a rapid clinical assessment paired with emergent imaging (usually non\u2010contrast head CT) to differentiate ischemic from hemorrhagic stroke. Other workup may include vascular imaging and laboratory tests to help classify the stroke type (e.g., using the TOAST criteria). The decision tree focuses on determining eligibility for reperfusion therapies.\n\n**Management Principles**\n\nCurrent American Heart Association/American Stroke Association guidelines support the use of intravenous thrombolysis (typically with recombinant tissue plasminogen activator, rtPA) in eligible patients presenting with acute ischemic stroke within 4.5 hours of symptom onset. Although antithrombotic therapy (e.g., aspirin) is essential for secondary prevention, it does not address the immediate need for reperfusion. In addition, prophylactic antiepileptics are not routinely recommended unless there is evidence of seizures or a high risk thereof. In pregnant or lactating patients, guidelines advise careful risk\u2013benefit evaluation; thrombolysis has been used in pregnancy in select cases after multidisciplinary consultation, and the management plan should be tailored to both maternal and fetal safety.\n\n**Option Analysis**\n\nOption A (Antiepileptic) would be chosen if the primary concern were seizure activity or seizure prophylaxis\u2014which is not the case unless seizures are present. Option B (Antithrombotic) is important for long\u2010term stroke prevention but does not serve as the acute intervention to restore cerebral blood flow. Option C, though not explicitly described in the question, is presumed to denote thrombolytic therapy (or a similarly aggressive reperfusion strategy) which is indicated immediately in eligible patients with acute ischemic stroke. Option D is not provided, and given the context, Option C is the superior and correct choice.\n\n**Clinical Pearls**\n\n\u2022 Time is brain: prompt administration of reperfusion therapy is crucial in acute ischemic stroke.  \u2022 Differentiating between immediate interventions (thrombolysis) and secondary preventive treatments (antithrombotics, antiepileptics) is essential in formulating an effective treatment plan.  \u2022 In special populations such as pregnant or breastfeeding patients, individualized risk assessment with input from relevant specialties is key.\n\n**Current Evidence**\n\nRecent guidelines underscore that intravenous thrombolysis improves outcomes when administered according to strict inclusion/exclusion criteria. Studies continue to support its benefit when used within the recommended time frame, and although data in pregnancy are more limited, case series and expert opinion support its cautious use when the potential benefits outweigh the risks. Continued research and advances in endovascular techniques further refine the acute management of stroke.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 277,
    "question": "pt with stroke and has marfinoid feature, what is the treatment:",
    "option_a": "vit B6",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nHomocystinuria is a hereditary metabolic disorder characterized by elevated blood homocysteine levels, often manifesting with marfanoid features (such as a long, thin body habitus), lens dislocation, and an increased risk of thromboembolic events including stroke. In pyridoxine (vitamin B6)\u2013responsive cases, high\u2010dose vitamin B6 is a cornerstone of therapy.\n\n**Pathophysiology**\n\nThe disorder is most commonly due to a deficiency in cystathionine beta\u2010synthase (CBS), which leads to impaired conversion of homocysteine to cystathionine. Elevated homocysteine damages vascular endothelium and predisposes patients to thrombosis. In cases that are pyridoxine responsive, vitamin B6 acts as an essential cofactor that enhances any residual CBS enzyme activity, thereby lowering homocysteine levels.\n\n**Clinical Correlation**\n\nPatients may present with thromboembolic events such as stroke at a young age alongside features resembling Marfan syndrome (marfanoid habitus) but with distinctive findings like downward lens dislocation (compared to the upward shift in Marfan syndrome). Recognizing these features directs the clinician to evaluate for homocystinuria, particularly in patients with cryptogenic stroke.\n\n**Diagnostic Approach**\n\nThe workup involves measuring plasma total homocysteine and methionine levels, along with urine amino acid analysis and potentially genetic testing. Differential diagnoses include Marfan syndrome (which shares a marfanoid habitus but lacks the metabolic abnormalities) and other connective tissue disorders.\n\n**Management Principles**\n\nFor pyridoxine-responsive homocystinuria, the first-line therapy is high-dose vitamin B6 supplementation. Treatment is typically accompanied by dietary methionine restriction and supplementation with folate and vitamin B12 to further reduce homocysteine levels. Pregnancy and lactation considerations: Vitamin B6, folate, and B12 are safe in pregnancy and lactation, and their use is encouraged to optimize metabolic control and reduce thrombotic risk.\n\n**Option Analysis**\n\nOption A (vitamin B6) is correct because it directly addresses the underlying enzyme deficiency in pyridoxine-responsive homocystinuria. The other options (which are not provided) are not relevant in the management of this condition.\n\n**Clinical Pearls**\n\n1. Homocystinuria can mimic Marfan syndrome but is distinguished by metabolic abnormalities and a higher thrombotic risk. 2. Downward lens subluxation is a key differentiator from Marfan syndrome. 3. Early identification and pyridoxine treatment can significantly reduce the risk of vascular complications.\n\n**Current Evidence**\n\nRecent studies and consensus guidelines continue to support the use of high-dose vitamin B6 in B6-responsive cases, with adjunctive nutritional therapy to manage homocysteine levels and prevent thrombotic events.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 278,
    "question": "Patient came with left side weakness; CT showed right semiovale hypodensity; what is the next step:",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAcute ischemic stroke evaluation relies on promptly excluding hemorrhage via a noncontrast CT scan and then assessing the vasculature for occlusive lesions. Computed tomography angiography (CTA) is the key imaging modality used to visualize cerebral arteries and identify large vessel occlusions.\n\n**Pathophysiology**\n\nIn ischemic stroke, occlusion of a cerebral artery leads to insufficient blood flow and tissue infarction. In this patient, a hypodensity in the right semiovale reflects an infarct in the white matter supplied by small or large vessels that can be further characterized with vascular imaging.\n\n**Clinical Correlation**\n\nThe clinical presentation of left-sided weakness correlates with right hemisphere impairment. CTA is used to confirm the presence of a vascular occlusion (or significant stenosis), which has implications for treatment options such as thrombolysis or mechanical thrombectomy.\n\n**Diagnostic Approach**\n\nAfter a noncontrast CT confirms the presence of an infarct and excludes hemorrhage, the next step is vascular imaging. CTA differentiates between large vessel occlusions, small vessel disease, and other etiologies like embolism. Differential diagnoses include lacunar infarcts (typically due to small vessel disease) and other stroke mimics.\n\n**Management Principles**\n\nAcute management of ischemic stroke includes consideration for intravenous thrombolysis, provided the patient is within the therapeutic window and there are no contraindications. CTA is essential for identifying candidates for endovascular thrombectomy in cases of large vessel occlusion. In pregnant or lactating patients, CT and CTA are used judiciously with appropriate fetal shielding and minimized radiation exposure when necessary, as the benefits usually outweigh the risks in acute settings.\n\n**Option Analysis**\n\nOption A (CTA) is correct because it is the most appropriate next step to evaluate the cerebral vasculature after detection of ischemic changes on the CT scan. Other options are either not provided or not appropriate at this stage.\n\n**Clinical Pearls**\n\n1. Rapid vascular imaging is critical in stroke management as 'time is brain'. 2. CTA helps in the diagnosis of large vessel occlusions which may be amenable to mechanical thrombectomy. 3. Distinguishing between stroke subtypes using imaging guides the choice of intervention.\n\n**Current Evidence**\n\nCurrent stroke guidelines endorse the use of CTA immediately after noncontrast CT in patients with suspected acute ischemic stroke, as it increases the detection of vascular occlusions and guides advanced therapeutic decisions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 279,
    "question": "pt with SLE + antiphospholipid presented with stroke for 2 days what you will give:",
    "option_a": "warfarin",
    "option_b": "Aspirin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nPatients with systemic lupus erythematosus (SLE) are at risk of developing antiphospholipid syndrome (APS), an autoimmune condition that significantly increases the risk of thrombotic events, including stroke. In APS, long-term anticoagulation is the mainstay of secondary prevention.\n\n**Pathophysiology**\n\nAPS is mediated by autoantibodies (lupus anticoagulant, anticardiolipin, and anti-\u03b22 glycoprotein I) that create a hypercoagulable state through various mechanisms, including endothelial cell activation and interference with the natural anticoagulant pathways. This predisposes patients to both arterial and venous thrombosis.\n\n**Clinical Correlation**\n\nThe patient, with a background of SLE and confirmed antiphospholipid antibodies, presents with stroke\u2014a common manifestation of APS. In such cases, anticoagulation is essential to prevent further thrombotic episodes.\n\n**Diagnostic Approach**\n\nDiagnosis of APS relies on both clinical criteria (history of thrombosis or pregnancy morbidity) and laboratory criteria (presence of antiphospholipid antibodies on two or more occasions 12 weeks apart). Differential diagnoses for stroke include atherosclerotic or cardioembolic causes, which are distinguished by the absence of antiphospholipid antibodies in these conditions.\n\n**Management Principles**\n\nFor patients with APS who have experienced a thrombotic event such as a stroke, long-term anticoagulation with warfarin is indicated, typically targeting an INR of 2.0\u20133.0 (or higher in cases of recurrent events). In the acute phase, bridging with heparin may be used until therapeutic INR is reached. Pregnancy and lactation considerations: Warfarin is contraindicated in pregnancy due to teratogenicity; therefore, pregnant patients are managed with low-molecular-weight heparin (LMWH) and low-dose aspirin instead.\n\n**Option Analysis**\n\nOption A (warfarin) is correct since anticoagulation is essential in APS-related strokes. Aspirin alone does not provide sufficient protection against recurrent thrombosis in APS. The other options are not provided and would not be appropriate as sole therapy.\n\n**Clinical Pearls**\n\n1. APS markedly increases the risk of recurrent thrombotic events and requires long-term anticoagulation. 2. Warfarin is typically preferred for non-pregnant patients, while LMWH is used in pregnancy. 3. Regular monitoring of INR is crucial to ensure adequate anticoagulation.\n\n**Current Evidence**\n\nRecent guidelines and clinical trials reaffirm warfarin as the treatment of choice for secondary prevention in APS, while also cautioning against the use of direct oral anticoagulants (DOACs) in this population due to potential reduced efficacy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 280,
    "question": "Another question about Patient came with stroke CT showed watershed infarction, next?",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nWatershed infarctions occur in regions at the boundaries of cerebral arterial territories and are typically caused by hypoperfusion, either from systemic hypotension or significant proximal arterial stenosis. Assessment of the vascular supply is essential in managing these infarctions.\n\n**Pathophysiology**\n\nWatershed strokes result from decreased cerebral blood flow in the border zones between major vascular territories (such as between the anterior, middle, and posterior cerebral arteries). This hypoperfusion may be secondary to conditions like severe carotid stenosis or systemic hypotension, leading to ischemia in these vulnerable regions.\n\n**Clinical Correlation**\n\nPatients with watershed infarctions may exhibit variable neurological deficits depending on the areas involved. Identifying the underlying cause is key, as treatment may differ if, for example, significant carotid stenosis is present.\n\n**Diagnostic Approach**\n\nAfter an initial noncontrast CT confirms a watershed infarct, the next step is to perform vascular imaging with CTA. This test assesses for carotid or intracranial stenosis, occlusions, and other vascular abnormalities. Differential diagnoses include small vessel occlusion or embolic strokes, which are distinguished based on vascular imaging findings.\n\n**Management Principles**\n\nManagement involves stabilizing the patient\u2019s hemodynamics, initiating antiplatelet therapy, and correcting underlying causes such as carotid stenosis if present. CTA plays a pivotal role in evaluating for significant vascular compromise that might require revascularization interventions. Pregnancy and lactation considerations: While CTA involves radiation, appropriate shielding and dose minimization can be used in pregnant and lactating patients when the benefits outweigh the risks in the context of acute stroke evaluation.\n\n**Option Analysis**\n\nOption A (CTA) is correct because it is the most appropriate next diagnostic step to assess the vascular status and identify potential reversible causes (e.g., carotid stenosis) underlying a watershed infarction. The absence of alternative options further supports this choice.\n\n**Clinical Pearls**\n\n1. Watershed infarcts often indicate underlying hemodynamic compromise rather than embolic events. 2. CTA is invaluable for evaluating carotid and intracranial vasculature in this setting. 3. Recognizing the pattern of watershed infarction can prompt timely interventions to improve cerebral perfusion.\n\n**Current Evidence**\n\nRecent stroke management guidelines emphasize the importance of early vascular imaging in all ischemic strokes, including watershed infarctions, to tailor appropriate therapies and identify candidates for potential revascularization procedures.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]